Adilene Olvera1, Hannah Carter2, Anubama Rajan2, Lily G Carlin1, Xiaomin Yu3, Xi-Lei Zeng3, Samuel Shelburne1, Micah Bhatti1, Sarah E Blutt2, Noah F Shroyer2, Robert Jenq4, Mary K Estes3, Anthony Maresso3, Pablo C Okhuysen1,5. 1. Department of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, Texas, USA. 3. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. 4. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5. Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
Abstract
BACKGROUND: The role of enteropathogenic Escherichia coli (EPEC) as a cause of diarrhea in cancer and immunocompromised patients is controversial. Quantitation of fecal bacterial loads has been proposed as a method to differentiate colonized from truly infected patients. METHODS: We studied 77 adult cancer and immunosuppressed patients with diarrhea and EPEC identified in stools by FilmArray, 25 patients with pathogen-negative diarrhea, and 21 healthy adults without diarrhea. Stools were studied by quantitative polymerase chain reaction (qRT-PCR) for EPEC genes eaeA and lifA/efa-1 and strains characterized for virulence factors and adherence to human intestinal enteroids (HIEs). RESULTS: Patients with EPEC were more likely to have community-acquired diarrhea (odds ratio, 3.82 [95% confidence interval, 1.5-10.0]; P = .008) compared with pathogen-negative cases. Although EPEC was identified in 3 of 21 (14%) healthy subjects by qPCR, the bacterial burden was low compared to patients with diarrhea (≤55 vs median, 6 × 104 bacteria/mg stool; P < .001). Among EPEC patients, the bacterial burden was higher in those who were immunosuppressed (median, 6.7 × 103 vs 55 bacteria/mg; P < .001) and those with fecal lifA/ifa-1 (median, 5 × 104 vs 120 bacteria/mg; P = .015). Response to antimicrobial therapy was seen in 44 of 48 (92%) patients with EPEC as the sole pathogen. Antimicrobial resistance was common and strains exhibited distinct patterns of adherence with variable cytotoxicity when studied in HIEs. Cancer care was delayed in 13% of patients. CONCLUSIONS: Immunosuppressed cancer patients with EPEC-associated diarrhea carry high burden of EPEC with strains that are resistant to antibiotics, exhibit novel patterns of adherence when studied in HIEs, and interfere with cancer care.
BACKGROUND: The role of enteropathogenic Escherichia coli (EPEC) as a cause of diarrhea in cancer and immunocompromised patients is controversial. Quantitation of fecal bacterial loads has been proposed as a method to differentiate colonized from truly infectedpatients. METHODS: We studied 77 adult cancer and immunosuppressed patients with diarrhea and EPEC identified in stools by FilmArray, 25 patients with pathogen-negative diarrhea, and 21 healthy adults without diarrhea. Stools were studied by quantitative polymerase chain reaction (qRT-PCR) for EPEC genes eaeA and lifA/efa-1 and strains characterized for virulence factors and adherence to human intestinal enteroids (HIEs). RESULTS:Patients with EPEC were more likely to have community-acquired diarrhea (odds ratio, 3.82 [95% confidence interval, 1.5-10.0]; P = .008) compared with pathogen-negative cases. Although EPEC was identified in 3 of 21 (14%) healthy subjects by qPCR, the bacterial burden was low compared to patients with diarrhea (≤55 vs median, 6 × 104 bacteria/mg stool; P < .001). Among EPEC patients, the bacterial burden was higher in those who were immunosuppressed (median, 6.7 × 103 vs 55 bacteria/mg; P < .001) and those with fecal lifA/ifa-1 (median, 5 × 104 vs 120 bacteria/mg; P = .015). Response to antimicrobial therapy was seen in 44 of 48 (92%) patients with EPEC as the sole pathogen. Antimicrobial resistance was common and strains exhibited distinct patterns of adherence with variable cytotoxicity when studied in HIEs. Cancer care was delayed in 13% of patients. CONCLUSIONS: Immunosuppressed cancerpatients with EPEC-associated diarrhea carry high burden of EPEC with strains that are resistant to antibiotics, exhibit novel patterns of adherence when studied in HIEs, and interfere with cancer care.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Doreen Baumann; Helen Salia; Lilo Greune; Stephanie Norkowski; Britta Körner; Zina M Uckeley; Gad Frankel; Marianne Guenot; Christian Rüter; M Alexander Schmidt Journal: Int J Med Microbiol Date: 2018-03-12 Impact factor: 3.473
Authors: Brianna Lindsay; John B Ochieng; Usman N Ikumapayi; Aliou Toure; Dilruba Ahmed; Shan Li; Sandra Panchalingam; Myron M Levine; Karen Kotloff; David A Rasko; Carolyn R Morris; Jane Juma; Barry S Fields; Michel Dione; Dramane Malle; Stephen M Becker; Eric R Houpt; James P Nataro; Halvor Sommerfelt; Mihai Pop; Joe Oundo; Martin Antonio; Anowar Hossain; Boubou Tamboura; O Colin Stine Journal: J Clin Microbiol Date: 2013-03-27 Impact factor: 5.948
Authors: Jennifer Foulke-Abel; Julie In; Jianyi Yin; Nicholas C Zachos; Olga Kovbasnjuk; Mary K Estes; Hugo de Jonge; Mark Donowitz Journal: Gastroenterology Date: 2015-12-08 Impact factor: 22.682
Authors: Ganesh Swaminathan; Nabiollah Kamyabi; Hannah E Carter; Anubama Rajan; Umesh Karandikar; Zachary K Criss; Noah F Shroyer; Matthew J Robertson; Cristian Coarfa; Chenlin Huang; Tate E Shannon; Madeleine Tadros; Mary K Estes; Anthony W Maresso; K Jane Grande-Allen Journal: Acta Biomater Date: 2021-07-17 Impact factor: 10.633